Valuation dashboard for Harvard Bioscience, Inc. (HBIO) with P/E N/A, P/B 4.86, EV/EBITDA -78.67 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Analysis Summary
Harvard Bioscience, Inc. reported revenue of $86.5M in the most recent fiscal year, growing at a 5-year CAGR of -3.3%.
Trailing-twelve-month margins: gross margin 58.2%, operating margin 1.2%, net margin -11.9%.
At the current price of $7.97, HBIO has negative trailing earnings (P/E not meaningful) and an ROE of -92.01%. Market capitalisation stands at $36M.
Balance sheet quality for HBIO: current ratio of 2.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.86 |
| EV / EBITDA | -78.67 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-18.81 |
| vs Current Price | -336.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HBIO | Harvard Bioscience, Inc. | $36M | 4.86 | -92.0% | |
| 0R29.L | Intuitive Surgical, Inc. | $135.9B | 74.05 | 11.86 | 17.8% |
| ISRG | Intuitive Surgical, Inc. | $135.1B | 44.13 | 7.62 | 17.8% |
| 0R19.L | Becton, Dickinson and Company | $52.5B | 33.21 | 2.19 | 6.6% |
| BDX | Becton, Dickinson and Company | $49.0B | 54.89 | 2.05 | 3.8% |
| RMD | ResMed Inc. | $33.1B | 22.81 | 5.23 | 23.9% |
| 0KW4.L | ResMed Inc. | $31.1B | |||
| MDLN | Medline Inc. | $27.6B | 38.36 | 2.44 | 10.8% |
Price
| Price | $7.97 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -92.01% |
| Return on Invested Capital | 1.91% |
| Return on Assets | -13.65% |
| Gross Margin | 58.16% |
| Operating Margin | 1.17% |
| Net Margin | -11.86% |
Related companies: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of HBIO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks